Serum Levels of Soluble CD23, but not Soluble CD25, Predict Disease Progression in Early Stage B-Cell Chronic Lymphocytic Leukemia

References

• Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: New insights into biology and therapy. Ann. Int. Med. 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternak B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberlin F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M. T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Montserrat E., Vinolas N., Reverter J. C., Rozman C. Natural history of chronic lymphocytic leukemia: On the progression and prognosis of early clinical stages. Nouv. Rev. Fr. Hematol. 1988; 30: 359–361
   PubMedGoogle Scholar
• Rozman C., Montserrat E., Rodriguez‐Fernandez J. M., Ayats R., Vallespi T., Parody R., Rios A., Prados D., Morey M., Gomis F., Alcala A., Guiterrez M., Maldonado J., Gonzalez C., Giralt M., Hernandez‐Nieto L., Cabrera A., Fernandez‐Rananda J. M. Bone marrow histologic pattern: The best single prognostic parameter in chronic lymphocytic leukemia. A multivariate analysis of 329 cases. Blood 1984; 64: 642–648
   PubMed Web of Science ®Google Scholar
• Montserrat E., Sanchez‐Bisono J., Vinolas N., Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: Analysis of its prognostic significance. Brit. J. Haematol 1986; 62: 567–575
   PubMed Web of Science ®Google Scholar
• Kallander C., Simonsson B., Hagberg B., Gronowitz J. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 1984; 54: 2450–2455
   PubMed Web of Science ®Google Scholar
• Simonsson B., Wibell L., Nilsson K. β2‐microglobulin in chronic lymphocytic leukemia. Stand. J. Haematol. 1980; 24: 174–180
   PubMedGoogle Scholar
• Juliusson G., Oscier D. G., Fitchett M., Ross F. M., Stockdill G., Mackie M. J., Parker A. C., Castoldi G. L., Cuneo A., Knuutila S., Elonen E., Gahrton G. Prognostic subgroups in B‐cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med. 1990; 323: 720–724
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Fitzpatrick J. E., O'Donnell A., Han T., Foon K. A., Bhargava A. Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. Leukemia 1992; 6: 1243–1245
   PubMed Web of Science ®Google Scholar
• Semenzato G., Siviero F., Vinante F., Zambello R., Trentin L., Agostini C., Adami F., Vincenzi C., Zanotti R., Zuppini B., Chilosi M., Pizzolo G. Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. Eur. J. Cancer Clin. Oncol. 1989; 25: 1577–1581
   PubMedGoogle Scholar
• Sarfati M., Bron D., Lagneaux L., Fonteyn C., Frost H., Delespesse G. Elevation of IgE‐binding factors in serum of patients with B cell‐derived chronic lymphocytic leukemia. Blood 1988; 71: 94–98
   PubMed Web of Science ®Google Scholar
• Semenzato G., Foa R., Agostini C., Zambelli R., Trentin L., Vinante F., Benedetti F., Chilosi M., Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987; 70: 396–400
   PubMed Web of Science ®Google Scholar
• van Oer's M. H. J., Pals S. T., Evers L. M., van der Schoot C. E., Koopman G., van Lier R. A. W. Expression and release of CD27 in human B‐cell malignancies. Blood 1993; 82: 3430–3436
   PubMed Web of Science ®Google Scholar
• Christiansen I., Gidlöf C., Wallgren A., Simonsson B., Tottermann T. H. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B‐lymphocytic leukemia and correlate with clinical stage and prognostic parameters. Blood 1994; 84: 3010–3016
   PubMed Web of Science ®Google Scholar
• Delespesse G., Suter U., Mossolayi D., Bettler B., Sarfati M., Hofstetter H., Kilcherr E., Debre P., Dalloul A. Expression, structure, and function of the CD23 antigen. Adv. Immunol 1991; 49: 149–191
   PubMed Web of Science ®Google Scholar
• Yokota A., Kikutani H., Tanaka T., Sato R., Barsumian E. L., Suemura M., Kishimoto T. Two species of human Fc‐receptor II (FcR II/CD23): Tissue‐specific and IL‐4‐specific regulation of gene expression. Cell 1988; 55: 611–618
   PubMed Web of Science ®Google Scholar
• Punnonen J., Aversa G., Cocks B. G., McKenzie A. N., Menon S., Zuwarski G., de Waal Malefyt R., de Vries J. E. Interleukin 13 induces interleukin 4‐independent IgG4 and IgE synthesis and CD23 expression by human B‐ cells. Proc. Natl. Acad. Sci. USA 1993; 90: 3730–3734
   PubMed Web of Science ®Google Scholar
• Sarfati M., Fournier S., Christoffersen M., Biron G. Expression of CD23 antigen and its regulation by IL‐4 in chronic lymphocytic leukemia. Leukemia Res. 1990; 14: 47–55
   PubMed Web of Science ®Google Scholar
• Fournier S., Tran I. D., Suter U., Biron G., Delespesse G., Sarfati M. The in vivo expression of type B CD23 mRNA in B‐chronic lymphocytic leukemia is associated with an abnormally low CD23 upregulation by IL‐4: comparison with their normal cellular counterparts. Leukemia Res. 1991; 15: 609–618
   PubMed Web of Science ®Google Scholar
• Nakajima T., Sarfati M., Delespesse G. Relationship between human IgE‐binding factors (IgE‐BF) and lymphocyte receptors for IgE. J. Immunol. 1987; 139: 848–854
   PubMed Web of Science ®Google Scholar
• Matutes E., Owusu‐Ankomah K., Morilla R., Marco J. G., Houlihan A., Que T. H., Catovsky D. The immunological profile of B‐cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Broder T., Waldmann T. A. A monoclonal antibody (anti‐Tac) reactive with activated and functionally mature T‐cells. I. Production of anti‐Tac monoclonal antibody and distribution of Tac+ cells. J. Immunol. 1981; 126: 1393–1397
   PubMed Web of Science ®Google Scholar
• Tsudo M., Uchiyama T., Uchino H. Expression of the Tac antigen on activated normal human B‐cells. J. Exp. Med. 1984; 160: 612–617
   PubMed Web of Science ®Google Scholar
• Herrmann F., Canistra S. A., Levine H., Griffin J. D. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon‐induced human leukemic and normal monocytic cells. J. Exp. Med. 1985; 162: 1111–1116
   PubMed Web of Science ®Google Scholar
• Jaques Y., LeMauff B., Boeffard F., Godard A., Solillou J. P. A soluble interleukin 2 receptor produced by a normal alloreactive human T‐cell clone binds interleukin 2 with low affinity. J. Immunol. 1987; 139: 2308–2316
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kuman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelsonm D. L. Soluble interleukin‐2‐receptors are released from activated human lymphoid cells in vitro. J. Immunol 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C., Keilholz U., Richter M., Andreesen R., Hunstein W. The interleukin‐2 receptor in human monocytes and macrophages: regulation of expression and release of the and chains (p55 and p75). Res. Immunol. 1992; 143: 33–37
   PubMedGoogle Scholar
• Ambrosetti A., Semenzato G., Prior M., Chilosi M., Vinante F., Vincenzi V., Zanotti R., Trentin L., Portuese A., Menestrina F., Perona G., Agostini C., Todeschini G., Pizzolo G. Serum levels of soluble interleukin‐2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Brit. J. Haematol. 1989; 73: 181–186
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin‐2 receptor in Non‐Hodgkin's lymphoma. Am. J. Clin. Pathol. 1989; 92: 186–191
   PubMed Web of Science ®Google Scholar
• Pui C. H., Schell M. J., Vodian M. A., Kline S., Mirro J., Christ W. M., Behm F. G. Serum CD4, CD8, and interleukin‐2 receptor levels in childhood acute myeloid leukemia. Leukemia 1991; 5: 249–254
   PubMed Web of Science ®Google Scholar
• Kay N. E., Burton J., Wagner D., Nelson D. L. The malignant B‐cells from B‐chronic lymphocytic leukemia patients release Tac‐soluble interleukin‐2 receptors. Blood 1988; 72: 447–450
   PubMed Web of Science ®Google Scholar
• Gronowitz J. S., Hagberg H., Källander C. F. R., Simonsson B. Optimized assay for thymidine kinase and its application for the detection of antibodies against herpes simplex virus type 1‐ and 2‐induced thymidine kinase. Infect. Immunol. 1980; 29: 425–434
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Ass. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Cox D. Regression models and life tables (with discussion). J. Royal Statist. Soc, series B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Reinisch W., Willheim M., Hilgarth M., Gasche C., Mader R., Szepfalusi S., Steger G., Berger R., Lechner K., Boltz‐Nitulescu G., Schwarzmeier J. D. Soluble CD23 reliably reflects disease activity in B‐cell chronic lymphocytic leukemia. J. Clin. Oncol. 1994; 12: 2146–2152
   PubMed Web of Science ®Google Scholar
• Beguin Y., Lampertz S., DeGroote D., Igot D., Malaise M., Fillet G. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in the serum of patients with chronic lymphocytic leukemia. Leukemia 1993; 7: 2019–2025
   PubMed Web of Science ®Google Scholar
• Knauf W. U., Raghavachar A., Zeigmeister B., Ludwig W. ‐D., Thiel E. Serum levels of sCD8, sCD25, and sCD23 in B‐cell chronic lymphocytic leukemia: Correlation with disease activity and tumor load. Cytokines in Hemopoiesis, Oncology, and Immunology III, M. Freund, H. Link, R. Schmidt, K. Welte. Springer Verlag, Berlin‐Heidelberg 1994; 435–436
   Google Scholar
• Musolino C., Di Cesare E., Alonci A., Allebra A., Orlando A., Grosso P., Squadrito G. Serum levels of CD8 antigen and soluble interleukin‐2‐receptor in patients with B‐cell chronic lymphocytic leukemia. Acta Haematol. 1991; 85: 57–61
   PubMed Web of Science ®Google Scholar
• Pangalis G. A., Roussou P. A., Kittas C., Kokkinou S., Fessas P. B‐chronic lymphocytic leukemias. Prognostic implication of bone marrow histology in 120 patients. Experience from a single hematology unit. Cancer 1987; 59: 767–771
   PubMed Web of Science ®Google Scholar
• Geisler C. H., Hou‐Jensen K., Myhre Jensen O., Tingaard‐Pedersen N., Mork Hansen M., Hansen N. E., Holm M., Egelund Christensen B., Drivsholm A., Boye Nielsen J., Thorling K., Andersen E., Larsen J. K., Kragh Andersen P. The bone marrow infiltration pattern in CD5+ B‐cell chronic lymphocytic leukemia has no independent prognostic significance. Blood 1994; 84: 2084, (abstract)
   Google Scholar
• Molica S., Alberti A. Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Confer 1987; 60: 2712–2716
   Google Scholar
• Källander C. F. R., Simonsson B., Gronowitz J. S., Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur. J. Haematol. 1987; 38: 331–337
   PubMed Web of Science ®Google Scholar
• Gronowitz J. S., Hagberg H., Källander C. F. R., Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non‐Hodgkin's lymphoma. Brit. J. Cancer 1983; 47: 487–495
   PubMed Web of Science ®Google Scholar
• Hagberg H., Glimelius B., Gronowitz J. S., Killander A., Kallander C. F. R., Schröder T. Biochemical markers in non‐Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand. J. Haematol. 1984; 33: 59–67
   PubMedGoogle Scholar
• Martinsson U., Glimelius B., Hagberg H., Sundstrom C. Primarily asymptomatic low‐grade non‐Hodgkin's lymphomas: prediction of symptom‐free survival and total survival. Eur. J. Haematol. 1989; 43: 332–338
   PubMed Web of Science ®Google Scholar
• Hallek M., Wanders L., Ostwald M., Busch R., Senekowitsch R., Stern S., Schick H. ‐D., Kuhn‐Hallek I., Emmerich B. Serum β2‐microglobulin and thymidine kinase are independent predictors of progression‐free survival in chronic lymphocytic leukemia and immuno‐cytoma. Leukemia & Lymphoma 1996; 22: 439–447
   PubMed Web of Science ®Google Scholar
• Aguilar‐Santelesis M., Loftenius A., Ljungh C., Svenson S. B., Andersson B., Mellstadt H., Jondal M. Serum levels of helper factors (IL‐1, IL‐1 and IL‐6), T‐cell products (sCD4 and sCD8), sIL‐2R and 2‐microglobulin in patients with B‐CLL and benign B lymphocytosis. Leukemia Res. 1992; 16: 607–613
   PubMed Web of Science ®Google Scholar
• Yawetz S., Cumberland W. G., van der Meyden M., Martinez‐Maza O. Elevated serum levels of soluble CD23 (sCD23) preceed the appearance of acquired immunodeficiency syndrome‐associated non‐Hodgkin's lymphoma. Blood 1995; 85: 1843–1849
   PubMed Web of Science ®Google Scholar
• French Cooperative Group On Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990; 75: 1414–1421
   PubMed Web of Science ®Google Scholar
• International Workshop On Chronic Lymphocytic Leukemia (IWCLL). Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann. Int. Med. 1989; 110: 236–238
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., Roller C., Talpaz M., Schachner J., Child C. C., Freireich E. J., McCredie K. B. Fludarabine: a new agent with marked cytore‐ductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2‐chloro‐2′‐deoxyadenosine in previously treated patients with B‐cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1994; 11: 679–689
   Web of Science ®Google Scholar
• Khouri I. F., Keating M. J., Vriesendorp H. M., Reading C. L., Przepiorka D., Huh Y. O., Andersson B. S., van Besien K. W., Mehra R. C., Giralt S. A., Ippoliti C., Marshall M., Thomas M. W., O'Brien S., Robertson L. E., Deisseroth A. B., Champlin R. E. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J. Clin. Oncol. 1994; 12: 748–758
   PubMed Web of Science ®Google Scholar